Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Sequenom, Inc.
SAN DIEGO, Sept. 18, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced a Certified Service Provider (CSP) program for the technical certification of selected laboratories offering research services using the Sequenom research-use-only MassARRAY® System. Certifications cover the major research applications of the MassARRAY System, including iPLEX® genotyping, OncoCarta™ somatic mutation profiling, ADME PGx, and EpiTyper® DNA methylation analysis.
"The use of the MassARRAY System in clinical and translational research continues to grow," said Michael Monko, Sequenom's Senior Vice President for Genetic Analysis. "Clinical and translational researchers require the greatest level of confidence in their data, and this program provides assurance in the quality of the work generated by our network of highly experienced certified providers."
The certifications have been awarded to the McGill University and Genome Quebec Innovation Centre in Montreal, Canada, Knight Diagnostic Laboratories at Oregon Health & Science University, and GeneWorks in Adelaide, Australia. Additional institutions have included The Clinical Genomics Centre in Toronto, Canada, Karolinska University Hospital in Sweden, NewGene in Newcastle, UK, DNA LandMarks (a plant and animal genomics company and subsidiary of BASF) based in Quebec, Canada, as well as several providers based in Asia.
"We are delighted to partner with Sequenom, and this certification confirms the high-quality standards we have implemented at the Innovation Centre over the years for our sequencing and genotyping services. We are especially proud of this CSP certification because we participated in the creation of the program and its implementation," said Daniel Tessier, Vice President, Technology Centres at Genome Quebec.
Sequenom's MassARRAY System is utilized by biomedical researchers worldwide to measure genetic variations that occur normally or in association with diseases including cancer. The MALDI-TOF based mass spectrometry technology enables scientists to utilize highly specific and sensitive pre-designed or custom-made research use assay panels for several key types of genomic markers, including single nucleotide polymorphisms, somatic mutations, copy number variations, gene expression, and DNA methylation.
For additional information, visit www.sequenom.com
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.
SEQUENOM®, MassARRAY®, iPLEX®. EpiTyper® and OncoCarta™ are registered trademarks of Sequenom, Inc.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding growth of the use of the MassARRAY system in clinical and translational research, the impact, benefits or results of using the MassARRAY system, and Sequenom's commitment to improving healthcare through revolutionary genetic analysis solutions, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of technology and tests such as the MaterniT21 PLUS test, reliance upon the collaborative efforts of other parties such as, without limitation, healthcare providers, international distributors and licensees, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's financial position, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, its most recently filed reports on Form 8-K, and its most recently filed Annual Report on Form 10-K, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
©2012 PR Newswire. All Rights Reserved.